度洛西汀对躯体型障碍患者认知功能P300的影响

目的 探讨度洛西汀对躯体型障碍患者认知功能的事件相关电位P300的影响.方法 随机将年龄在18～65岁符合CCMD-3躯体型障碍诊断标准患者30例作为实验组,选择30例性别年龄健康者作为对照组.实验组予度洛西汀治疗6周.各组分别予听觉P300检测,比较P300潜伏期及波幅的差异.结果 实验组PZ 点潜伏期（308±21）ms均比对照组（298±22）ms延长,实验组FZ 、CZ 、PZ、OZ点分别为（2.4±1.6）μV、（2.6±2.3）μV、（2.6±3.3）μV、（2.4±1.9）μV,波幅均比对照组降低,分别为（3.9±2.1）μV、（3.8±1.9）μV、（4.2±3.4）μV、（3.7±2.0）μV,（P〈0.05及0.01）.治疗8周后,实验组PZ 点潜伏期（299±20）ms明显缩短,FZ 、CZ 、PZ、OZ点波幅明显升高,分别为（3.4±1.7）μV、（3.7±2.2）μV、（3.9±3.3）μV、（3.5±1.8）μV（P〈0.05）.结论 躯体型障碍患者存在认知功能障碍,度洛西汀具有改善躯体型障碍认知功能的作用.

Effect of duloxetine on cognitive function P300 in somatoform disorders

Objective To investigate character of cognitive function in somatoform disorders with event-related potential P300. Methods 30 patients （among 18-65 years old） met with CCMD-3 for somatoform disorders criteria were recruited as research group. 30 marched sexual and age healthy adolescents were selected as normal control group. Research group were treated with Duloxetine for 8 weeks. All groups were measured with auditory evoked event-related potential P300. P300 latencies and amplitudes of all groups were compared with respectively. Results P3 latencies prolonged and the amplitudes of FZ, CZ , PZ and OZ site shortened in research group compared with normal control group （ P 〈 0. 05 or P 〈 0. 01）. After 8 week treatment, P3 latencies shortened and the amplitudes of FZ, CZ, PZ and OZ site raised in research group （P〈 0.05）. Conclusions Somatoform disorders presents impaired cognitive function measured with event--related potential P300. Duloxetine can improve cognitive impairment in Somatoform disorders.